Plans to list etomidate as illegal drug: Ong Ye Kung, Typhoon Wipha causes major flight disruptions: Singapore live news
Currently, etomidate is listed under the Poisons Act. Under this law, abusers face only a fine. Sellers face possible jail time of up to two years. Ong said this will be done in the coming weeks. He added that it will be an interim measure until further changes can be made to the law to tackle the vaping scourge in Singapore. Read more about why there are plans to list etomidate under the MDA.
Typhoon Wipha toppled trees and caused major flight disruptions Sunday (20 July) in Hong Kong and at some nearby airports in China as it moved west off the southern coast of the country. Earlier on Sunday morning, the Hong Kong Observatory issued a hurricane signal No. 10, its highest warning. Find out more about Typhoon Wipha, which was later downgraded to a severe tropical storm.
Read more in our live blog below, including the latest local and international news and updates:
MOH, MHA working to list etomidate as illegal drug: Ong Ye Kung
Singapore's Health and Home Affairs Ministries are working to list etomidate, which is being abused via e-vaporisers, under the Misuse of Drugs Act (MDA), Health Minister Ong Ye Kung said on Sunday (20 July).
This paves the way for abusers and traffickers of Kpods – vapes containing etomidate – to be treated in the same way as those who abuse or traffic drugs like nimetazepam (Erimin-5), with mandatory rehabilitation and jail time for repeat offenders.
Currently, etomidate is listed under the Poisons Act. Under this law, abusers face only a fine. Sellers face possible jail time of up to two years.
Ong said this will be done in the coming weeks. He added that it will be an interim measure until further changes can be made to the law to tackle the vaping scourge in Singapore.
Read more about why there are plans to list etomidate under the MDA.
Typhoon Wipha causes damage, disrupt flights, before weakening to severe tropical storm
Typhoon Wipha toppled trees and caused major flight disruptions Sunday (20 July) in Hong Kong and at some nearby airports in China as it moved west off the southern coast of the country. Earlier on Sunday morning, the Hong Kong Observatory issued a hurricane signal No. 10, its highest warning.
Airports in Hong Kong, Shenzhen, Zhuhai and the casino hub of Macao canceled or postponed flights for most of the day, according to their websites. Hong Kong grounded at least 400 flights, affecting around 80,000 passengers, broadcaster RTHK said. Some high-speed train services were also suspended.
The typhoon stayed just offshore until about 6 pm, when it made landfall in a coastal area of Taishan city in Guangdong province, China's National Meteorological Center said. It then weakened to a severe tropical storm with maximum sustained winds of 108 kph.
Singapore's Health and Home Affairs Ministries are working to list etomidate, which is being abused via e-vaporisers, under the Misuse of Drugs Act (MDA), Health Minister Ong Ye Kung said on Sunday (20 July).
This paves the way for abusers and traffickers of Kpods – vapes containing etomidate – to be treated in the same way as those who abuse or traffic drugs like nimetazepam (Erimin-5), with mandatory rehabilitation and jail time for repeat offenders.
Currently, etomidate is listed under the Poisons Act. Under this law, abusers face only a fine. Sellers face possible jail time of up to two years.
Ong said this will be done in the coming weeks. He added that it will be an interim measure until further changes can be made to the law to tackle the vaping scourge in Singapore.
Read more about why there are plans to list etomidate under the MDA.
Typhoon Wipha causes damage, disrupt flights, before weakening to severe tropical storm
Typhoon Wipha toppled trees and caused major flight disruptions Sunday (20 July) in Hong Kong and at some nearby airports in China as it moved west off the southern coast of the country. Earlier on Sunday morning, the Hong Kong Observatory issued a hurricane signal No. 10, its highest warning.
Airports in Hong Kong, Shenzhen, Zhuhai and the casino hub of Macao canceled or postponed flights for most of the day, according to their websites. Hong Kong grounded at least 400 flights, affecting around 80,000 passengers, broadcaster RTHK said. Some high-speed train services were also suspended.
The typhoon stayed just offshore until about 6 pm, when it made landfall in a coastal area of Taishan city in Guangdong province, China's National Meteorological Center said. It then weakened to a severe tropical storm with maximum sustained winds of 108 kph.
Typhoon Wipha toppled trees and caused major flight disruptions Sunday (20 July) in Hong Kong and at some nearby airports in China as it moved west off the southern coast of the country. Earlier on Sunday morning, the Hong Kong Observatory issued a hurricane signal No. 10, its highest warning.
Airports in Hong Kong, Shenzhen, Zhuhai and the casino hub of Macao canceled or postponed flights for most of the day, according to their websites. Hong Kong grounded at least 400 flights, affecting around 80,000 passengers, broadcaster RTHK said. Some high-speed train services were also suspended.
The typhoon stayed just offshore until about 6 pm, when it made landfall in a coastal area of Taishan city in Guangdong province, China's National Meteorological Center said. It then weakened to a severe tropical storm with maximum sustained winds of 108 kph.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
an hour ago
- Medscape
What Factors Influence a Patient's Success on GLP-1s?
Longer treatment duration, not having diabetes, and using semaglutide were among the factors associated with better weight reduction over 12 months among patients taking GLP-1 receptor agonists (RA), a cohort study suggested. 'Treatment responses differ among patients receiving GLP-1 RAs, and the weight fluctuations and associated factors following [their] use have not been adequately characterized,' Linong Ji, MD, of Peking University People's Hospital in Beijing, China, told Medscape Medical News . The findings, published online in Diabetes, Obesity and Metabolism , 'may provide novel insights into weight fluctuations after GLP-1 RA treatment in a real-world setting,' he said, potentially advancing the development of individualized strategies for patients. 'Corroborates Other Studies' Researchers conducted a real-world, single-center, retrospective study of 679 patients with overweight or obesity who initiated GLP-1 RA treatment between November 2022 and October 2024. At baseline, participants had a mean age of 37 years, and 31% were men. The mean BMI was 33.4, and 21% were diagnosed with diabetes. The GLP-1 RAs used in the study included semaglutide (Ozempic), liraglutide (Victoza), lixisenatide (Lyxumia), beinaglutide (Yishengtai), exenatide (Bydureon), dulaglutide (Trulicity), and PEG-loxenatide (Fulaimei). All were available for participants with both type 2 diabetes (T2D) and overweight/obesity. For participants with overweight/obesity but without T2D, only Ozempic or Victoza were routinely prescribed, with off-label documentation and informed consent. Weight measurements were collected during in-person clinic visits, and weight fluctuation curves were stratified into three phenotypes — Successful Weight Reduction, Remaining Stable, and Weight Regain. Subsequently, the association between potential influencing factors and weight fluctuations was estimated by univariate and multivariate logistic regression. Subgroup analyses were performed in participants with obesity, prediabetes, and in those using liraglutide or semaglutide. Researchers found significant differences in the duration of GLP-1 RA treatment across groups at the 3-, 6-, and 12-month follow-ups. The Successful Weight Reduction group had a significantly longer duration of GLP-1 RA treatment than the Remaining Stable group and a longer duration at both the 6- and 12-month follow-ups than the Weight Regain group. Diabetes status also showed group differences. At both the 3- and 6-month follow-ups, the proportion of patients with T2D in the Successful Weight Reduction group was lower than in the Remaining Stable group. Types of GLP-1 RAs varied between groups, and at the 3- and 6-month follow-ups, the Successful Weight Reduction group was more likely to have initiated treatment with semaglutide than the Remaining Stable group. Patients with a longer duration of GLP-1 RA treatment (odds ratio [OR], 1.014) and higher Homeostasis Model Assessment of Beta-Cell Function levels (OR, 4.912) were more likely to achieve successful weight reduction at the 12-month follow-up. Nondiabetic status (OR, 2.176) and using semaglutide (OR, 2.138) were associated with successful weight reduction at the 6-month follow-up. In addition, a higher percentage of body fat in both men (OR, 3.990) and women (OR, 2.266) was associated with successful weight reduction. The weight regain group had a higher baseline estimated glomerular filtration rate than the Successful Weight Reduction group and the Remaining Stable group at 3-month follow-up, especially among participants with prediabetes. Ji said this finding surprised him. Patients with obesity often exhibit a state of renal hyperfiltration, characterized by elevated renal plasma flow and glomerular filtration rate, which can be reversed by weight reduction. The finding suggests that patients with renal hyperfiltration might be less likely to experience durable weight reduction, Ji said. 'However, few studies have revealed similar observations. Therefore, further validations and investigations are still needed for this finding.' Furthermore, the team found a positive nonlinear association of serum creatinine with successful weight reduction at 12 months — a finding that will also require additional investigations to examine the mechanism underlying the association. Overall, Ji concluded that while longer duration of GLP-1 RA treatment using semaglutide, nondiabetic status, and higher percentage of body fat might be associated with better weight reduction, 'basal metabolic rate, skeletal muscle mass, muscle mass of the abdomen and limbs, and serum creatinine were nonlinearly associated with the probability of successful weight reduction.' Randy Seeley, MD, Henry King Ransom Endowed Professor of Surgery, Internal Medicine, and Nutritional Sciences at the University of Michigan School of Medicine, Ann Arbor, Michigan, and director of the National Institutes of Health-funded Michigan Nutrition Obesity Research Center, told Medscape Medical News , 'The main results of the study agree with what the field has already seen. Although it is a relatively small study, it corroborates other larger studies,' said Seeley, who was not involved in the study. This work was supported by the Noncommunicable Chronic Diseases-National Science and Technology Major Project. Ji reported receiving fees for lecture presentations and for consulting from AstraZeneca, Merck, Metabasis, MSD, Novartis, Eli Lilly and Company, Roche, Sanofi-Aventis, and Takeda. Seeley reported that his lab has worked with both Novo and Lilly (and others trying to enter the space), and he has also served as a paid consultant for both of those companies (and others trying to enter the space).
Business Wire
4 hours ago
- Business Wire
Pfizer Completes Licensing Agreement with 3SBio
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. ( granting Pfizer exclusive rights for the development, manufacturing and commercialization of 3SBio's SSGJ-707, a bispecific antibody targeting PD-1 and VEGF developed using 3SBio's proprietary CLF2 platform. This agreement solidifies Pfizer at the forefront of innovative cancer research and further enhances the company's robust oncology pipeline. 'We are excited to contribute our significant expertise and resources to advance rapidly the development of the SSGJ-707 program including novel combination strategies across a number of our major tumor areas of focus,' said Chris Boshoff, M.D., Ph.D., Chief Scientific Officer and President, Research & Development, Pfizer. 'This is an important candidate that combines two key targets in a promising class of medicines, complementing our antibody-drug conjugate portfolio and further demonstrates our commitment to advancing pioneering science to deliver transformative cancer medicines and new hope to people living with cancer.' SSGJ-707 is currently undergoing several clinical trials in China for non-small cell lung cancer (NSCLC), metastatic colorectal cancer, and gynecological tumors. Positive interim Phase 2 results evaluating the safety and efficacy of SSGJ-707 as monotherapy in patients with advanced NSCLC were recently presented at the American Society of Clinical Oncology (ASCO) Annual Meeting. Pfizer plans to manufacture drug substance for SSGJ-707 in Sanford, North Carolina, and drug product in McPherson, Kansas. The clinical development plan for SSGJ-707 moving forward will include trial sites across the U.S. and rest of world with priority to the Phase 3 global development plan for NSCLC and other solid tumors. The first Phase 3 global studies will initiate enrollment in the U.S. Under the terms of the agreement, 3SBio will receive a payment of $1.25 billion. Pfizer will also make a $100 million equity investment in 3SBio. Additionally, the agreement provides Pfizer the option to extend the license to include exclusive development and commercialization rights to SSGJ-707 in China. In exchange for the exclusive rights in China, Pfizer will pay 3SBio up to $150 million in option payments. For additional background on the licensing deal, please read the announcement press release here. About Pfizer Oncology At Pfizer Oncology, we are at the forefront of a new era in cancer care. Our industry-leading portfolio and extensive pipeline includes three core mechanisms of action to attack cancer from multiple angles, including small molecules, antibody-drug conjugates (ADCs), and bispecific antibodies, including other immune-oncology biologics. We are focused on delivering transformative therapies in some of the world's most common cancers, including breast cancer, genitourinary cancer, hematology-oncology, and thoracic cancers, which includes lung cancer. Driven by science, we are committed to accelerating breakthroughs to help people with cancer live better and longer lives. About Pfizer: Breakthroughs That Change Patients' Lives At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For 175 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at In addition, to learn more, please visit us on and follow us on X at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Disclosure Notice: The information contained in this release is as of July 24, 2025. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. This release contains forward-looking information about, among other topics, Pfizer Oncology, SSGJ-707, an investigational bispecific antibody targeting PD-1 and VEGF, a global, ex-China, licensing agreement between Pfizer and 3SBio, Inc. granting Pfizer exclusive rights for the development, manufacturing and commercialization of SSGJ-707, and an option to extend the license to include exclusive development and commercialization rights to SSGJ-707 in China, including their potential benefits, manufacturing plans and development plans, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, risks related to the ability to realize the anticipated benefits of the transaction, including the possibility that the expected benefits from the transaction will not be realized or will not be realized within the expected time period; risks related to the successful integration of the licensed asset with Pfizer's business; disruption from the transaction making it more difficult to maintain business and operational relationships; negative effects of this announcement or the consummation of the transaction on the market price of Pfizer's common stock and/or operating results; significant transaction costs; unknown liabilities; the risk of litigation and/or regulatory actions related to the transaction or SSGJ-707; manufacturing capabilities or capacity; other business effects and uncertainties, including the effects of industry, market, business, economic, political or regulatory conditions; future exchange and interest rates; risks and uncertainties related to issued or future executive orders or other new, or changes in, laws, regulations or policy; changes in tax and other laws, regulations, rates and policies; the uncertainties inherent in business and financial planning, including, without limitation, risks related to Pfizer's business and prospects, adverse developments in Pfizer's markets, or adverse developments in the U.S. or global capital markets, credit markets, regulatory environment, tariffs and other trade policies or economies generally; future business combinations or disposals; uncertainties regarding the commercial success of SSGJ-707 and Pfizer's commercialized and pipeline products; the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; risks associated with preliminary or interim data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from the clinical studies; whether and when drug applications may be filed in any jurisdictions for SSGJ-707 or any of Pfizer's pipeline products for any potential indications; whether and when any such applications may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product's benefits outweigh its known risks and determination of the product's efficacy and, if approved, whether SSGJ-707 or any such other products will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of SSGJ-707 or any such other products; uncertainties regarding the impact of COVID-19; and competitive developments. A further description of risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in its subsequent reports on Form 10-Q, including in the sections thereof captioned 'Risk Factors' and 'Forward-Looking Information and Factors That May Affect Future Results', as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at and
News24
7 hours ago
- News24
Chinese fraud fugitive arrested in Sandton after Interpol Red Notice
A 57-year-old Chinese fugitive was arrested and has appeared in court following a global search initiated by Interpol, police said on Thursday. Police spokesperson Lieutenant Colonel Amanda van Wyk said the man had been linked to a fraud case in China and had been evading police in that country and in South Africa. Van Wyk said the Interpol National Central Bureau (NCB) Pretoria extradition team arrested the man in Sandton on Tuesday. 'According to a preliminary report, Interpol circulated a Red Notice to all member countries to locate and provisionally arrest the Chinese national. 'The suspect reportedly applied for a visa at the United States of America embassy in Sandton when his fugitive status was flagged, leading to his arrest on Tuesday,' van Wyk said. The man made his first appearance in the Randburg Magistrate's Court on Wednesday.
